Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Darktrace
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jan 2026: Jill Popelka stepped down as Darktrace CEO, with board chair Charles Goodman named interim CEO while a permanent successor is sought. Darktrace has been owned by Thoma Bravo since its take-private completed in Oct 2024.
Cyber & information governance
No data breaches, regulator action or newly published product vulnerabilities involving Darktrace found in HSH's search of the last 24 months; the most recent CVE listed against its products dates from Jul 2023. NHS DSPT status not yet checked.
Regulatory & clinical safety
Cyber security software supplier; no regulatory or clinical safety actions found in the last 24 months.
Contract performance
No significant NHS contracts, terminations or customer disputes involving Darktrace found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.